Get started
Work

Reply

Year: 2019
Type: letter
Abstract: We thank Ms Brown and Dr Gutierrez for their comments regarding our recent publication of the ASBMT CRS and ICANS Consensus Grading [1], and we agree that there are significant clinical differences between patients requiring a low dose versus a high dose of 1 vasopressor. This was an active area of discussion among the larger group. However, we expressly stated that the Consensus Grading is not a treatment guideline, and no inference in such regard should be made. Rather, grading of CRS is entirely dependent on the interventions the patient requires and is not meant as a tool to suggest one intervention or another.
DOI: 10.1016/j.bbmt.2019.03.019
Authors: Daniel W. Lee, Elena Mead, Bianca D. Santomasso, Cameron J. Turtle, Stephan A. Grupp, Sattva S. Neelapu
Institutions: University of Virginia, Memorial Sloan Kettering Cancer Center, Fred Hutch Cancer Center, Children's Hospital of Philadelphia, University of Pennsylvania, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
Funders: Pfizer, GlaxoSmithKline, Merck, Novartis, Gilead Sciences, Celgene, Unum Therapeutics, Servier, Eurostars
OpenAlex ID: W4249729613
Cites: 3
Cited by:
Related to: 10